Nkarta’s (NKTX) “Buy” Rating Reaffirmed at HC Wainwright

Nkarta (NASDAQ:NKTX)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research report issued on Thursday,Benzinga reports. They currently have a $18.00 price target on the stock. HC Wainwright also issued estimates for Nkarta’s Q4 2025 earnings at ($0.29) EPS and FY2029 earnings at ($0.99) EPS.

Separately, Needham & Company LLC reiterated a “buy” rating and set a $11.00 price target on shares of Nkarta in a report on Thursday. Six equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Nkarta currently has an average rating of “Buy” and a consensus target price of $14.86.

Nkarta Price Performance

Nkarta stock opened at $2.00 on Thursday. Nkarta has a fifty-two week low of $1.31 and a fifty-two week high of $11.84. The firm’s 50 day simple moving average is $1.99 and its 200-day simple moving average is $2.87. The company has a market cap of $141.14 million, a P/E ratio of -1.06 and a beta of 0.90.

Nkarta (NASDAQ:NKTX) last announced its earnings results on Wednesday, March 26th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.06. On average, analysts expect that Nkarta will post -1.7 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Paul J. Hastings sold 17,378 shares of the company’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $2.20, for a total value of $38,231.60. Following the sale, the chief executive officer now owns 319,859 shares of the company’s stock, valued at $703,689.80. The trade was a 5.15 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 8.70% of the company’s stock.

Hedge Funds Weigh In On Nkarta

Several institutional investors have recently added to or reduced their stakes in NKTX. Wasatch Advisors LP raised its holdings in shares of Nkarta by 31.7% in the third quarter. Wasatch Advisors LP now owns 1,834,680 shares of the company’s stock valued at $8,293,000 after buying an additional 442,125 shares during the last quarter. Geode Capital Management LLC increased its position in Nkarta by 3.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,171,026 shares of the company’s stock valued at $5,294,000 after acquiring an additional 33,927 shares in the last quarter. JPMorgan Chase & Co. raised its position in Nkarta by 252.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,063,362 shares of the company’s stock worth $4,806,000 after purchasing an additional 761,349 shares during the last quarter. Franklin Resources Inc. bought a new stake in shares of Nkarta during the third quarter worth $151,000. Finally, FMR LLC raised its holdings in Nkarta by 97.1% during the 3rd quarter. FMR LLC now owns 133,149 shares of the company’s stock worth $602,000 after purchasing an additional 65,600 shares during the last quarter. 80.54% of the stock is owned by institutional investors.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.